Pharmaceutical Technology

JUNE 23, 2022

It functions as a molecular scissor by slicing long chains of virus’ polypeptide proteins into smaller component proteins. The increased infection rate of Covid-19 indicates the requirement for an alternative treatment development pipeline instead of the intensive process to launch new drugs to market, the researchers said.

Drugs 130

Drugs Protein Genome Genomics 130

pharmaphorum

JANUARY 6, 2022

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.

RNA 52

RNA Licensing Licensing Development 52

pharmaphorum

JANUARY 5, 2022

The new vaccine differs from the currently approved shots because it delivers antigens for both the spike protein and other proteins found in SARS-CoV-2. That could mean it is less susceptible to the loss of efficacy to vaccines that can occur when there are changes in the spoke protein – as witnessed with the new Omicron variant.

Protein 126

Protein Vaccination Vaccine Immune Response 126

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The market for mRNA-based vaccines and therapeutics is projected to grow from $46.7 RNA technology is not new nor has its potential been surprising.

Life Science 98

Life Science RNA Vaccination Vaccine 98

Pharmaceutical Technology

FEBRUARY 1, 2023

However, caution must be taken, especially while bringing new mAbs to market, to avoid the potentially serious consequences of inducing novel viral mutations and further antibody-resistant strains of RSV. As an RNA virus, like SARS-CoV-2, RSV is highly prone to mutations.

Vaccination 162

Vaccination Vaccine Antibody Protein 162

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

pharmaphorum

JANUARY 10, 2022

Previously, messenger RNA (mRNA) therapies were a niche part of the global R&D pipeline, now a wide section of the public is at least familiar with the name of this type of therapy. Prior to the pandemic, biotech had a market cap of around $6.5bn whereas, at present, it is now valued at approximately $144bn.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

Roots Analysis

SEPTEMBER 9, 2024

Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccine Vaccination Development 40

pharmaphorum

DECEMBER 13, 2021

One of its other scientific legacies was the specific development and approval of mRNA vaccines, the first in that drug class on the market. Since their launch, they have dominated the Covid-19 vaccine market due to their first-to-market status, efficacy and safety profiles and manufacturing success. It may have sold its 7.7%

RNA 105

RNA Vaccination Vaccine Development 105

pharmaphorum

DECEMBER 1, 2020

The filing for a conditional marketing authorisation completed the rolling submission process that began on October 6. The EMA has also confirmed it has received a filing from Moderna, which is producing a rival vaccine based on similar RNA technology.

Vaccine 88

Vaccine Vaccination RNA Clinical Trials 88

XTalks

JANUARY 3, 2024

In individuals affected by ATTR, which includes both hereditary and wild-type (non-hereditary) variants, the TTR protein forms fibrils that accumulate in various tissues. These tissues comprise peripheral nerves, the heart, gastrointestinal system, eyes, kidneys, central nervous system, thyroid and bone marrow.

FDA Approval 105

FDA Approval Protein RNA Clinical Trials 105

pharmaphorum

JANUARY 7, 2022

billion licensing agreement with Ionis that gave it rights to eplontersen , a follow-up to Ionis’ already-marketed Tegsedi (inotersen) for polyneuropathy, another common complication of ATTR. Tafamidis is thought to work by stabilising the misfolded proteins. The new agreement comes just days after AZ closed a $3.1

Antibody 116

Antibody Licensing Licensing Protein 116

pharmaphorum

MARCH 9, 2022

BIVV001 is a factor VIII replacement therapy that is being developed as a successor to Eloctate (efmoroctocog alfa), Sanofi and Sobi’s current factor VIII drug that is dosed every four days but has seen its sales decline in an increasingly competitive market. The half life of the new drug – one of the main draws for Sanofi’s $11.6

Protein 98

Protein Gene Therapy Sales Regulation 98

pharmaphorum

OCTOBER 31, 2022

VRG50635 was discovered using Verge’s AI-powered discovery platform ConVERGE which maps out the biological underpinnings of diseases using data on DNA, RNA and protein profiles to identify new targets and drug that can interact with them. Alice Zhang.

Genomics 136

Genomics Genome Drugs RNA 136

XTalks

NOVEMBER 22, 2021

Related: How RNA-Based Pesticides Can Improve Pest Control. Once the army of Black Soldier flies has finished feasting, Bardee transforms the leftovers into “all-natural protein and oil for pet food, poultry and aqua feed and nutrient-rich organic fertilizers,” according to the company’s website.

Protein 98

Protein RNA Engineer Production 98

XTalks

JUNE 5, 2023

Abrysvo is an unadjuvanted vaccine and is composed of two preF proteins selected to optimize protection against RSV A and B strains. “A In February 2023, Pfizer revealed that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Abrysvo. billion in value by 2024, and grow to $9.53

Vaccine 98

Vaccine Vaccination FDA Approval Protein 98

Pfizer

JANUARY 27, 2023

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus.

Marketing 75

Marketing Production Drugs Licensing 75

pharmaphorum

NOVEMBER 10, 2021

Not so, says the NIH, which argues that three of its scientists – John Mascola, Barney Graham and Kizzmekia Corbett – should be named as co-inventors of the messenger RNA sequence coding for the SARS-CoV-2 spike protein that is the main component of Moderna’s mRNA-1273 shot. The patent has been filed but not yet awarded.

Vaccination 105

Vaccination Vaccine Scientist Protein 105

Pharmaceutical Technology

FEBRUARY 1, 2023

A major breakthrough from the National Institutes of Health (NIH), in mapping the structure of the RSV protein significantly changed the landscape, allowing companies to leap into RSV drug research with better efficacy results. However, subsequent RSV drugs, like Medimmune’s motavizumab, failed in clinical trials.

Vaccine 162

Vaccine Vaccination Antibody Development 162

Delveinsight

FEBRUARY 8, 2021

Analysts at DelveInsight expect major changes in the Cystic Fibrosis market landscape in the foreseeable future. The major factors shaping the market outlook include prevalence, monopoly of a pharma company, diagnostics and screening methodologies, entry of other market players in the Cystic Fibrosis market domain, as well as restraints.

Marketing 52

Marketing Development Production Drugs 52

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA.

Vaccine 52

Vaccine Vaccination DNA Protein 52

Delveinsight

JANUARY 18, 2021

The present Angelman syndrome treatment market revolves around the management of symptoms rather than curing the condition. . Several pharmaceutical and biotech companies in the Angelman syndrome market are exploring the novel curative approaches.

Marketing 52

Marketing Gene Drugs Protein 52

Worldwide Clinical Trials

MAY 30, 2024

Since marketing authorization for the first breakthrough treatment in 1994, the steady increase in clinical trials reflects the community’s commitment to finding effective ALS treatments despite the numerous hurdles associated with clinical trial design, from proof-of-concept to pivotal trials. Director, Therapeutic Area Medical Lead.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein.

Vaccination 111

Vaccination Vaccine Doctor Doctors 111

pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5

Gene Silencing 66

Gene Silencing Gene RNA Contract Manufacturing 66

Delveinsight

JULY 29, 2021

The acquisition of Teneobio will bolster their ability to develop innovative medicines to treat patients with serious illnesses and to bring to market best-in-class products, particularly concerning multispecific and bispecific medicines directed against targets in a broad range of diseases across their core therapeutic areas, as said by David M.

Drugs 98

Drugs Protein Life Science Development 98

Roots Analysis

FEBRUARY 13, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

pharmaphorum

MARCH 1, 2021

COVID-19 antigen tests diagnose active infection by detecting SARS-CoV-2 viral proteins in samples, as opposed to PCR tests which detect viral RNA and require lab processing, but can miss infections with low virus levels.

In-Vitro 98

In-Vitro RNA Protein Antibody 98

pharmaphorum

NOVEMBER 17, 2020

Both Pfizer and Moderna vaccines use synthetic messenger RNA to activate the immune system against the virus. They both code for the “Spike” protein seen on the surface of the SARS-CoV-2 coronavirus, which causes the body to produce antibodies that neutralise the virus in the event of an infection.

Vaccine 78

Vaccine Vaccination RNA Clinical Trials 78

Delveinsight

AUGUST 6, 2020

The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Among the 7MM geographies, the US accounted for the 54% share of the total hATTR market size. Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood.

Protein 52

Protein Gene Silencing Marketing Gene 52

XTalks

OCTOBER 26, 2023

variant was selected in June and within a few months, both Pfizer-BioNTech and Moderna were able to get vaccines for it to market by September, which Dr. Kierstead says is “astonishingly fast.” The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA.

Vaccine 105

Vaccine Vaccination RNA Manufacturing 105

The Pharma Data

OCTOBER 14, 2020

is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.

Protein 52

Protein RNA Production Genetics 52

pharmaphorum

DECEMBER 16, 2020

Like Pfizer/BioNTech’s BNT-162b, Moderna’s mRNA-1273 is based on messenger RNA coding for the SARS-CoV-2 spike protein, and will be administered in a two-dose regimen given a few weeks apart.

Vaccination 98

Vaccination Vaccine Trials RNA 98

pharmaphorum

SEPTEMBER 21, 2020

The drug works by reducing the production of ApoC-III, a protein that regulates plasma triglycerides. Akcea – an affiliate of Ionis that is set to become a wholly-owned subsidiary shortly – specialises in antisense drugs that target RNA to prevent the expression of errant genes that cause diseases.

Drugs 80

Drugs RNA Medicine Genetics 80

Roots Analysis

AUGUST 28, 2022

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. Likely Growth of the Spatial Omics Solutions Market. Our Social Media Platform.

Genomics 52

Genomics Genome RNA Genome Project 52

pharmaphorum

FEBRUARY 19, 2021

billion cumulative doses of its NVX-CoV2373 recombinant protein-based vaccine candidate, which is yet to be approved by regulators. It can be stored at standard refrigerator temperatures and does not require the ultra-cool supply chain required to maintain stability of RNA vaccines from Pfizer/BioNTech and Moderna.

Vaccine 80

Vaccine Vaccination Manufacturing RNA 80